Sify.com » Topics » Biocon
Biocon News
Biocon Dec-qtr net profit falls 15%; shares fall
Shares in Biocon Ltd, India's top-listed biotechnology company, fell as much as 4.4 percent on Wednesday, after its December quarter net profit fell 15 percent on lower licensing income, which the company expects to rise in future. The Bangalore-based drugmaker's consolidated net profit fell to 848 million rupees, much below estimates, in the fiscal third quarter ended December 31 from 1.01 billion
Shares in Biocon Ltd, India's top-listed biotechnology company, fell as much as 4.4 percent on Wednesday, after its December quarter net profit fell 15 percent on lower licensing income, which the company expects to rise in future. The Bangalore-based drugmaker's consolidated net profit fell to 848 million rupees, much below estimates, in the fiscal third quarter ended December 31 from 1.01 billion
Biocon sees larger licensing income from pharma
Biocon Ltd, India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said on Wednesday. Get real! India
Biocon Ltd, India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said on Wednesday. Get real! India
Biocon Q3 net down 15.8 pct, lags estimates
Three months ended Dec 31 (Versus the same period a year earlier, in billion rupees unless stated) Net Profit 0.85 vs 1.01 The all-new Swift Dzire StraitsRevenue 5.32 vs 5.19 Results are
Three months ended Dec 31 (Versus the same period a year earlier, in billion rupees unless stated) Net Profit 0.85 vs 1.01 The all-new Swift Dzire StraitsRevenue 5.32 vs 5.19 Results are
Biocon’s Nine-Month Revenues Driven by Growth in Branded Formulations, Emerging Markets and Research Services
Commenting on the results, Chairman and Managing Director Kiran Mazumdar-Shaw stated, “Our performance in the first 3 quarters of FY12 has been good on the manufacturing & services fronts where profits were up nearly 29% (excluding licensing income). Licensing income, however, was sharply down from the exceptional levels recorded last fiscal which resulted in flat earnings overall. As I have frequently stated, licensing income is a timing issue and subject to periodic variability. We have seen exceptional growth in our Research Services business, an outcome of the strategic investments we have made in enhancing our integrated service offerings. Moving up the value chain is integral to our growth strategy which is reflected in the strong growth delivered by our Branded Formulations vertical. Our focus on Emerging Markets is also enabling us to realize a greater potential for our APIs and Insulins portfolios. Our R&D pipeline is advancing satisfactorily with 2 late-stage candidates and several early stage programs with enormous value creation potential through licensing. We have shaped our broad-based business into key growth verticals, which we believe will enable us to deliver sustainable, long-term value to our shareholders.”
Commenting on the results, Chairman and Managing Director Kiran Mazumdar-Shaw stated, “Our performance in the first 3 quarters of FY12 has been good on the manufacturing & services fronts where profits were up nearly 29% (excluding licensing income). Licensing income, however, was sharply down from the exceptional levels recorded last fiscal which resulted in flat earnings overall. As I have frequently stated, licensing income is a timing issue and subject to periodic variability. We have seen exceptional growth in our Research Services business, an outcome of the strategic investments we have made in enhancing our integrated service offerings. Moving up the value chain is integral to our growth strategy which is reflected in the strong growth delivered by our Branded Formulations vertical. Our focus on Emerging Markets is also enabling us to realize a greater potential for our APIs and Insulins portfolios. Our R&D pipeline is advancing satisfactorily with 2 late-stage candidates and several early stage programs with enormous value creation potential through licensing. We have shaped our broad-based business into key growth verticals, which we believe will enable us to deliver sustainable, long-term value to our shareholders.”
India’s First ever Legal Counsel Awards takes place in Mumbai
The Ideas Exchange, in association with Lex Witness, India's 1st Magazine on Legal and Corporate Affairs presented India’s first ever awards to recognize and honor the excellence amongst the corporate legal fraternity – the Legal Counsel India Awards today.
The Ideas Exchange, in association with Lex Witness, India's 1st Magazine on Legal and Corporate Affairs presented India’s first ever awards to recognize and honor the excellence amongst the corporate legal fraternity – the Legal Counsel India Awards today.
India’s First ever Legal Counsel Awards takes place in Mumbai
The Ideas Exchange, in association with Lex Witness, India's 1st Magazine on Legal and Corporate Affairs presented India’s first ever awards to recognize and honor the excellence amongst the corporate legal fraternity – the Legal Counsel India Awards today.
The Ideas Exchange, in association with Lex Witness, India's 1st Magazine on Legal and Corporate Affairs presented India’s first ever awards to recognize and honor the excellence amongst the corporate legal fraternity – the Legal Counsel India Awards today.
© Copyright Sify Technologies Ltd, 1998-2011. All rights reserved. India News Portal, Sify.com hosted at SifyHosting India's first Level 3 Internet Data Centre.
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise